STOCK TITAN

Iveric Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Very Positive)
Tags
Rhea-AI Summary

Iveric Bio (NASDAQ: ISEE) announced on October 1, 2021, the granting of equity-based awards to eight newly-hired employees as part of its 2019 Inducement Stock Incentive Plan. These inducement grants include non-statutory stock options for 375,000 shares and two tranches of 49,000 restricted stock units. The stock options have an exercise price of $16.65 and will vest over four years. Iveric Bio focuses on developing innovative treatments for retinal diseases, aiming to address significant unmet medical needs in the field.

Positive
  • Granting of stock options and restricted stock units indicates a strategic move to retain talent.
  • The exercise price of $16.65 aligns with Iveric Bio's stock price, potentially enhancing employee motivation.
Negative
  • None.

NEW YORK--(BUSINESS WIRE)-- IVERIC bio, Inc. (NASDAQ: ISEE) today reported that on October 1, 2021, the Company granted equity-based awards pursuant to the Company’s 2019 Inducement Stock Incentive Plan to eight newly-hired, non-executive employees. The inducement grants were approved by the Company’s compensation and talent strategy committee pursuant to a delegation by the Company’s board of directors and were made as a material inducement to the employee’s acceptance of employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4) as a component of his or her employment compensation.

The inducement grants consisted of non-statutory stock options to purchase an aggregate of 375,000 shares of the Company’s common stock and two separate tranches of an aggregate of 49,000 restricted stock units for shares of the Company’s common stock.

The stock options each have an exercise price of $16.65 per share, equal to the closing price of Iveric Bio’s common stock on October 1, 2021. The stock options each have a ten-year term and vest over four years, with 25% of the shares underlying each option vesting on October 1, 2022 and an additional 2.0833% of the shares underlying each option vesting at the end of each successive month thereafter. Grants in the first tranche of 18,000 restricted stock units each vest with respect to 25% of the shares underlying the applicable grant on each of October 1, 2022, October 1, 2023, October 1, 2024 and October 1, 2025. Grants in the second tranche of 31,000 restricted stock units each vest with respect to 100% of the shares underlying the applicable grant on October 1, 2022. The vesting of each grant is subject to the employee’s continued service with the Company through the applicable vesting date. The inducement grants are subject to the terms and conditions of award agreements covering the grants and the Company’s 2019 Inducement Stock Incentive Plan.

Iveric Bio

Iveric Bio is a science-driven biopharmaceutical company focused on the discovery and development of novel treatment options for retinal diseases with significant unmet medical needs. The Company is currently developing both therapeutic product candidates for age-related retinal diseases and gene therapy product candidates for orphan inherited retinal diseases. Vision is Our Mission. For more information on the Company, please visit www.ivericbio.com.

ISEE-G

Investor / Media Contact:

Iveric Bio

Kathy Galante, 212-845-8231

Senior Vice President, Investor Relations

kathy.galante@ivericbio.com

Media Contact:

SmithSolve

Alex Van Rees, 973-442-1555 ext. 111

alex.vanrees@smithsolve.com

Source: IVERIC bio, Inc.

FAQ

What equity awards were granted by Iveric Bio on October 1, 2021?

Iveric Bio granted stock options for 375,000 shares and 49,000 restricted stock units to newly-hired employees.

What is the exercise price for the stock options granted by Iveric Bio?

The exercise price for the stock options is $16.65 per share.

How will the stock options granted by Iveric Bio vest?

The stock options will vest over four years, with 25% vesting on October 1, 2022, and the remainder vesting monthly thereafter.

What does Iveric Bio focus on in its business?

Iveric Bio is focused on developing treatments for retinal diseases with significant unmet medical needs.

ISEE

NASDAQ:ISEE

ISEE Rankings

ISEE Latest News

ISEE Stock Data

5.51B
136.61M
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
New York